Company: CERO
Filing Date: 2025-01-14
Form Type: 424B3
Source: 0001213900-25-003435
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-14
Form: 424B3
Chunk 2
---

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |

| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |

| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |

| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                    |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share                              |     | CERO              |     | NASDAQ Global Market                      |
| Warrants, each whole warrant exercisable for one share of common stock |     | CEROW             |     | NASDAQ Capital Market                     |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Reference is hereby made to
the Current Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. (the “Company”) on December 31, 2024, pursuant to
which the Company reported the receipt of proceeds exercises of certain warrants to purchase shares of Series A Preferred Stock and issuances
of shares pursuant to the Company’s committed equity financing facility (the “Equity Line”) through December 30, 2024.

As a result of the receipt
of such proceeds and the receipt of additional proceeds from sales pursuant to the Equity Line through January 6, 2025, the Company now
reports a cash balance of approximately $5.463 million as of January 7, 2025.

<div align